MAPT and amyloidosis: Neuropathological measures include CERAD neuritic amyloid plaque scores, Braak staging for tau pathology, arteriolosclerosis, atherosclerosis, cerebral amyloid angiopathy (CAA), microinfarcts, gross infarcts/lacunes, and APOE (apolipoprotein) ε4 carrier status.